Novartis AG (NVS)
NYSE: NVS · IEX Real-Time Price · USD
97.44
-1.62 (-1.64%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Novartis AG Employees
Novartis AG had 76,057 employees on December 31, 2023. The number of employees decreased by 25,646 or -25.22% compared to the previous year.
Employees
76,057
Change (1Y)
-25,646
Growth (1Y)
-25.22%
Revenue / Employee
$656,402
Profits / Employee
$200,442
Market Cap
190.64B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
Dec 31, 2016 | 118,393 | -307 | -0.26% |
Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Pfizer | 88,000 |
Merck & Co. | 72,000 |
Danaher | 63,000 |
AbbVie | 50,000 |
NVS News
- 3 days ago - Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies - GlobeNewsWire
- 3 days ago - Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors - GlobeNewsWire
- 3 days ago - Novartis Exceeds Q1 Forecasts, Boosts Outlook as Blockbuster Drug Sales Climb - Investopedia
- 4 days ago - Novartis shares jump as drugmaker boosts outlook - Market Watch
- 4 days ago - Shares of Novartis climb 4.8% on raised guidance, better-than-expected results - CNBC
- 4 days ago - Novartis Ups Guidance on Profit, Sales Growth - WSJ
- 4 days ago - Novartis lifts FY guidance after Q1 results beat expectations - Reuters
- 4 days ago - Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised - GlobeNewsWire